v3.25.2
Sale of Technology and Other Assets - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
May 01, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Gain on sale of technology and other assets   $ 5,666 $ 0 $ 5,666 $ 0  
Equity securities received from sale of technology and other assets   1,591   1,591   $ 0
DCx Biotherapeutics Corporation            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Gain on sale of technology and other assets $ 5,700          
Milestones and sales royalties payments upon contingencies   0   0    
Upfront payment received on sale of technology and other assets 1,000          
Near-term payment 3,000          
Fair value of the consideration received 6,200          
Consideration receivable from sale of technology and other assets $ 3,000          
Equity ownership percentage received from sale of technology and other assets 9.99%          
Equity securities received from sale of technology and other assets $ 1,600          
Dilution protection rights received on sale of technology and other assets 600 $ 600   $ 600    
Cost of contracts transferred to acquirer on sale of technology and other assets (500)          
Cost of equipment sold and intellectual property out-licensed $ 0